Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2026-02-11 Sale | 2026-02-13 09:23 am | Apellis Pharmaceuticals Inc. | APLS | DeLong Mark Jeffrey Chief Business & Strat Officer | 368 | $22.15 | $8,153 | 114,591 (Direct) | View |
| 2026-01-22 Sale | 2026-01-23 4:13 pm | Apellis Pharmaceuticals Inc. | APLS | Baumal Caroline Chief Medical Officer | 2,797 | $21.77 | $60,878 | 86,527 (Direct) | View |
| 2026-01-22 Sale | 2026-01-23 4:12 pm | Apellis Pharmaceuticals Inc. | APLS | Chopas James George VP/Chief Accounting Officer | 2,064 | $21.77 | $44,924 | 49,805 (Direct) | View |
| 2026-01-22 Sale | 2026-01-23 4:11 pm | Apellis Pharmaceuticals Inc. | APLS | DeLong Mark Jeffrey Chief Business & Strat Officer | 3,371 | $21.77 | $73,371 | 78,353 (Direct) | View |
| 2026-01-22 Sale | 2026-01-23 4:10 pm | Apellis Pharmaceuticals Inc. | APLS | Deschatelets Pascal Chief Scientific Officer | 5,928 | $21.77 | $129,025 | 1,151,382 (Direct) | View |
| 2026-01-22 Sale | 2026-01-23 4:09 pm | Apellis Pharmaceuticals Inc. | APLS | Francois Cedric Chief Executive Officer | 27,192 | $21.77 | $591,845 | 1,600,467 (Indirect Direct) | View |
| 2026-01-22 Sale | 2026-01-23 4:08 pm | Apellis Pharmaceuticals Inc. | APLS | Nicholson Nur Chief Technical Officer | 7,725 | $21.77 | $168,138 | 71,118 (Direct) | View |
| 2026-01-22 Sale | 2026-01-23 4:07 pm | Apellis Pharmaceuticals Inc. | APLS | Sullivan Timothy Eugene Chief Financial Officer | 10,287 | $21.77 | $223,901 | 154,297 (Indirect Direct) | View |
| 2026-01-22 Sale | 2026-01-23 4:05 pm | Apellis Pharmaceuticals Inc. | APLS | Watson David O. General Counsel | 7,832 | $21.77 | $170,467 | 148,667 (Indirect Direct) | View |
| 2026-01-20 Sale | 2026-01-21 4:19 pm | Apellis Pharmaceuticals Inc. | APLS | Baumal Caroline Chief Medical Officer | 1,882 | $19.79 | $37,250 | 89,324 (Direct) | View |
| 2026-01-20 Sale | 2026-01-21 4:18 pm | Apellis Pharmaceuticals Inc. | APLS | Chopas James George VP/Chief Accounting Officer | 726 | $19.79 | $14,370 | 51,869 (Direct) | View |
| 2026-01-20 Sale | 2026-01-21 4:17 pm | Apellis Pharmaceuticals Inc. | APLS | DeLong Mark Jeffrey Chief Business & Strat Officer | 1,334 | $19.79 | $26,404 | 81,724 (Direct) | View |
| 2026-01-20 Sale | 2026-01-21 4:16 pm | Apellis Pharmaceuticals Inc. | APLS | Deschatelets Pascal Chief Scientific Officer | 909 | $19.79 | $17,992 | 1,157,310 (Direct) | View |
| 2026-01-20 Sale | 2026-01-21 4:14 pm | Apellis Pharmaceuticals Inc. | APLS | Francois Cedric Chief Executive Officer | 8,182 | $19.79 | $161,946 | 1,627,659 (Indirect Direct) | View |
| 2026-01-20 Sale | 2026-01-21 4:12 pm | Apellis Pharmaceuticals Inc. | APLS | Nicholson Nur Chief Technical Officer | 2,203 | $19.79 | $43,604 | 78,843 (Direct) | View |
| 2026-01-20 Sale | 2026-01-21 4:10 pm | Apellis Pharmaceuticals Inc. | APLS | Sullivan Timothy Eugene Chief Financial Officer | 2,892 | $19.79 | $57,241 | 164,584 (Indirect Direct) | View |
| 2026-01-20 Sale | 2026-01-21 4:08 pm | Apellis Pharmaceuticals Inc. | APLS | Watson David O. General Counsel | 2,475 | $19.79 | $48,987 | 156,499 (Indirect Direct) | View |
| 2026-01-13 Sale | 2026-01-15 4:34 pm | Apellis Pharmaceuticals Inc. | APLS | Chopas James George VP/Chief Accounting Officer | 873 | $22.19 | $19,369 | 52,595 (Direct) | View |
| 2026-01-13 Sale | 2026-01-15 4:33 pm | Apellis Pharmaceuticals Inc. | APLS | DeLong Mark Jeffrey Chief Business & Strat Officer | 1,780 | $22.19 | $39,493 | 83,058 (Direct) | View |
| 2026-01-13 Sale | 2026-01-15 4:32 pm | Apellis Pharmaceuticals Inc. | APLS | Deschatelets Pascal Chief Scientific Officer | 2,277 | $22.19 | $50,520 | 1,158,219 (Direct) | View |
| 2026-01-13 Sale | 2026-01-15 4:31 pm | Apellis Pharmaceuticals Inc. | APLS | Francois Cedric Chief Executive Officer | 10,186 | $22.19 | $225,999 | 1,635,841 (Indirect Direct) | View |
| 2026-01-13 Sale | 2026-01-15 4:30 pm | Apellis Pharmaceuticals Inc. | APLS | Nicholson Nur Chief Technical Officer | 2,618 | $22.19 | $58,086 | 81,046 (Direct) | View |
| 2026-01-13 Sale | 2026-01-15 4:29 pm | Apellis Pharmaceuticals Inc. | APLS | Sullivan Timothy Eugene Chief Financial Officer | 3,856 | $22.19 | $85,554 | 167,476 (Indirect Direct) | View |
| 2026-01-13 Sale | 2026-01-15 4:28 pm | Apellis Pharmaceuticals Inc. | APLS | Watson David O. General Counsel | 5,780 | $22.19 | $128,242 | 158,974 (Indirect Direct) | View |
| 2026-01-05 Sale | 2026-01-06 4:06 pm | Apellis Pharmaceuticals Inc. | APLS | Baumal Caroline Chief Medical Officer | 3,020 | $25.53 | $77,097 | 91,206 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2026-02-03 Exercise | 2026-02-05 4:14 pm | N/A 2026-02-06 | Apellis Pharmaceuticals Inc. | APLS | Francois Cedric Chief Executive Officer | 8,840 | $0 | 1,805,259 (Direct) | View |
| 2026-02-03 Exercise | 2026-02-05 4:14 pm | N/A N/A | Apellis Pharmaceuticals Inc. | APLS | Francois Cedric Chief Executive Officer | 8,840 | $3.76 | 1,805,259 (Direct) | View |
| 2026-01-28 Option Award | 2026-01-30 4:13 pm | N/A N/A | Apellis Pharmaceuticals Inc. | APLS | Boucher Kelley Chief People Officer | 30,146 | $0 | 127,804 (Direct) | View |
| 2026-01-28 Option Award | 2026-01-30 4:12 pm | N/A N/A | Apellis Pharmaceuticals Inc. | APLS | Chopas James George VP/Chief Accounting Officer | 16,150 | $0 | 65,955 (Direct) | View |
| 2026-01-28 Option Award | 2026-01-30 4:11 pm | N/A N/A | Apellis Pharmaceuticals Inc. | APLS | DeLong Mark Jeffrey Chief Business & Strat Officer | 36,606 | $0 | 114,959 (Direct) | View |
| 2026-01-28 Option Award | 2026-01-30 4:10 pm | N/A N/A | Apellis Pharmaceuticals Inc. | APLS | Deschatelets Pascal Chief Scientific Officer | 25,840 | $0 | 1,177,222 (Direct) | View |
| 2026-01-28 Option Award | 2026-01-30 4:09 pm | N/A N/A | Apellis Pharmaceuticals Inc. | APLS | MELTZER LESLIE Chief Research and Development | 45,220 | $0 | 107,024 (Direct) | View |
| 2026-01-28 Option Award | 2026-01-30 4:08 pm | N/A N/A | Apellis Pharmaceuticals Inc. | APLS | Nicholson Nur Chief Technical Officer | 45,220 | $0 | 116,338 (Direct) | View |
| 2026-01-28 Option Award | 2026-01-30 4:07 pm | N/A N/A | Apellis Pharmaceuticals Inc. | APLS | Sullivan Timothy Eugene Chief Financial Officer | 58,140 | $0 | 212,437 (Direct) | View |
| 2026-01-28 Option Award | 2026-01-30 4:06 pm | N/A N/A | Apellis Pharmaceuticals Inc. | APLS | Watson David O. General Counsel | 55,986 | $0 | 204,653 (Direct) | View |
| 2026-01-28 Option Award | 2026-01-30 4:05 pm | N/A N/A | Apellis Pharmaceuticals Inc. | APLS | Francois Cedric Chief Executive Officer | 195,952 | $0 | 1,796,419 (Direct) | View |
| 2026-01-07 Exercise | 2026-01-09 6:48 pm | N/A 2028-02-15 | Apellis Pharmaceuticals Inc. | APLS | Watson David O. General Counsel | 888 | $0 | 178,754 (Direct) | View |
| 2026-01-07 Exercise | 2026-01-09 6:48 pm | N/A N/A | Apellis Pharmaceuticals Inc. | APLS | Watson David O. General Counsel | 888 | $14.95 | 178,754 (Direct) | View |
| 2026-01-01 Option Award | 2026-01-05 4:42 pm | N/A 2033-12-31 | Apellis Pharmaceuticals Inc. | APLS | Machiels Alec Director | 22,645 | $0 | 811,623 (Direct) | View |
| 2026-01-01 Option Award | 2026-01-05 4:39 pm | N/A 2033-12-31 | Apellis Pharmaceuticals Inc. | APLS | Dunlop A. Sinclair Director | 22,645 | $0 | 176,251 (Direct) | View |
| 2026-01-01 Option Award | 2026-01-05 4:38 pm | N/A 2033-12-31 | Apellis Pharmaceuticals Inc. | APLS | Chan Gerald Director | 22,645 | $0 | 40,350 (Direct) | View |
| 2026-01-01 Option Award | 2026-01-05 4:37 pm | N/A 2033-12-31 | Apellis Pharmaceuticals Inc. | APLS | O'Brien Stephanie Monaghan Director | 22,645 | $0 | 40,350 (Direct) | View |